Jump to content

Akathisia

From Wikipedia
akathisia
Subclass ofpsychomotor agitation Edit
Health specialtyneurology Edit

Akathisia (/æ.kə.ˈθɪ.si.ə/ a-kə-THI-see-ə) be a movement disorder[1]wey be characterized by a subjective feeling of inner restlessness wey be accompanied by mental distress den/anaa an inability to sit still.[2][3] Usually, de legs most be prominently affected.[4] Those wey be affected fi fidget, rock back den forth, anaa pace,[5] while sam fi just get an uneasy feeling insyd dema bodies.[4] De most severe cases fi result in poor adherence to medications, exacerbation of psychiatric symptoms, den, secof dis, aggression, violence, den/anaa suicidal thoughts.[4] Akathisia sanso be associated plus threatening behaviour den physical aggression insyd mentally disordered patients.[6] However, de attempts to find potential links between akathisia den emerging suicidal anaa homicidal behaviour no be systematic wey be mostly based on a limited number of case reports den small case series.[7] Apart from dese few low-quality studies, der be anoda more recent den better quality study (a systematic review from 2021)[7] wey dey conclude akathisia no fi be reliably linked to de presence of suicidal behavior insyd patients dem treat plus antipsychotic medication.[7]

Antipsychotic medication, particularly de first generation antipsychotics, be a leading cause.[3][5] Oda agents commonly responsible for dis side-effect sanso fi include selective serotonin reuptake inhibitors, metoclopramide, den reserpine, though any medication wey dey list agitation as a side effect fi trigger am.[4][8] E sanso fi occur upon stopping antipsychotics.[4] De underlying mechanism be believed to involve dopamine.[4] Wen antidepressants be de cause, der be no agreement on de distinction between activation syndrome den akathisia.[9] Akathisia often be included as a component of activation syndrome.[9] However, de two phenomena no be de same since de former, namely antipsychotic-induced akathisia, dey suggest a known neuroreceptor mechanism (e.g., dopamine-receptor blockade).[9] Diagnosis be based on de symptoms.[4] E dey differ from restless leg syndrome insyd dat akathisia no be associated plus sleeping. However, despite a lack of historical association between restless leg syndrome den akathisia, dis no dey guarantee say de two conditions no dey share symptoms insyd individual cases.[4]

If akathisia be caused by an antipsychotic, treatment fi include switching to an antipsychotic plus a lower risk of de condition.[4] De antidepressant mirtazapine, although paradoxically associate plus de development of akathisia insyd sam individuals, demonstrate benefit,[1] as have diphenhydramine, trazodone, benzatropine, cyproheptadine, den beta blockers, particularly propranolol.[4][3][10]

Na dem first use de term by Czech neuropsychiatrist Ladislav Haškovec, wey describe de phenomenon insyd 1901 long before de discovery of antipsychotics, wey dem firstbdescribe drug-induced akathisia insyd 1960.[11] E be from Greek a-, wey dey mean "not", den καθίζειν kathízein, wey dey mean "to sit", anaa insyd oda words an "inability to sit".[4]

References

[edit | edit source]
  1. 1 2 Poyurovsky M, Weizman A (June 2020). "Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists". Drugs (Review). 80 (9): 871–882. doi:10.1007/s40265-020-01312-0. PMID 32385739. S2CID 218541032.
  2. Forcen, FE; Matsoukas, K; Alici, Y (February 2016). "Antipsychotic-induced akathisia in delirium: A systematic review". Palliative & Supportive Care (Review). 14 (1): 77–84. doi:10.1017/S1478951515000784. PMC 5516628. PMID 26087817.
  3. 1 2 3 Laoutidis, ZG; Luckhaus, C (May 2014). "5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis". The International Journal of Neuropsychopharmacology (Review). 17 (5): 823–32. doi:10.1017/S1461145713001417. PMID 24286228.
  4. 1 2 3 4 5 6 7 8 9 10 11 Lohr, JB; Eidt, CA; Abdulrazzaq Alfaraj, A; Soliman, MA (December 2015). "The clinical challenges of akathisia". CNS Spectrums (Review). 20 (Suppl 1): 1–14, quiz 15–6. doi:10.1017/S1092852915000838. PMID 26683525. S2CID 4253429.
  5. 1 2 Thomas, JE; Caballero, J; Harrington, CA (2015). "The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis". Current Neuropharmacology (Review). 13 (5): 681–91. doi:10.2174/1570159x13666150115220221. PMC 4761637. PMID 26467415.
  6. Stubbs, J. H.; Hutchins, D. A.; Mountjoy, C. Q. (2000). "Relationship of akathisia to aggressive and self-injurious behaviour: A prevalence study in a UK tertiary referral centre". International Journal of Psychiatry in Clinical Practice. 4 (4): 319–325. doi:10.1080/13651500050517894. ISSN 1365-1501. PMID 24926584. S2CID 26486432.
  7. 1 2 3 Kalniunas, Arturas; Chakrabarti, Ipsita; Mandalia, Rakhee; Munjiza, Jasna; Pappa, Sofia (2021-12-03). "The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review". Neuropsychiatric Disease and Treatment. 17: 3489–3497. doi:10.2147/NDT.S337785. ISSN 1176-6328. PMC 8651045. PMID 34887662.
  8. "MISSD - The Medication-Induced Suicide Prevention and Education Foundation in Memory of Stewart Dolin - Akathisia Support". missd.co. Retrieved 2022-08-26.
  9. 1 2 3 Amitai, Maya; Chen, Alon; Weizman, Abraham; Apter, Alan (2015-03-01). "SSRI-Induced Activation Syndrome in Children and Adolescents—What Is Next?". Current Treatment Options in Psychiatry (in English). 2 (1): 28–37. doi:10.1007/s40501-015-0034-9. ISSN 2196-3061.
  10. Fischel, T.; Hermesh, H.; Aizenberg, D.; Zemishlany, Z.; Munitz, H.; Benjamini, Y.; Weizman, A. (December 2001). "Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study". Journal of Clinical Psychopharmacology. 21 (6): 612–615. doi:10.1097/00004714-200112000-00013. ISSN 0271-0749. PMID 11763011. S2CID 22663143.
  11. Salem H, Nagpal C, Pigott T, Teixeira AL (2017). "Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges". Curr Neuropharmacol (Review). 15 (5): 789–798. doi:10.2174/1570159X14666161208153644. PMC 5771055. PMID 27928948.
[edit | edit source]